Semi-Annual Consolidated Statement Of Cash Flows

STELLA PHARMA CORPORATION - Filing #7248023

Concept 2024-04-01 to
2025-03-31
As at
2025-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-137,869,000 JPY
-760,976,000 JPY
Depreciation
34,723,000 JPY
35,039,000 JPY
Interest expenses
4,082,000 JPY
2,084,000 JPY
Increase (decrease) in provision for bonuses
-109,000 JPY
-655,000 JPY
Decrease (increase) in trade receivables
-638,438,000 JPY
-16,939,000 JPY
Decrease (increase) in inventories
-114,472,000 JPY
-175,660,000 JPY
Increase (decrease) in trade payables
-52,976,000 JPY
26,620,000 JPY
Subtotal
143,865,000 JPY
-875,132,000 JPY
Interest paid
-4,082,000 JPY
-2,084,000 JPY
Income taxes paid
-2,862,000 JPY
-2,851,000 JPY
Net cash provided by (used in) operating activities
140,408,000 JPY
-876,837,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-3,913,000 JPY
-10,978,000 JPY
Other, net
-10,000 JPY
180,000 JPY
Net cash provided by (used in) investing activities
287,576,000 JPY
-9,010,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
730,500,000 JPY
JPY
Repayments of long-term borrowings
-946,520,000 JPY
-160,008,000 JPY
Purchase of treasury shares
-26,000 JPY
JPY
Net cash provided by (used in) financing activities
721,253,000 JPY
228,353,000 JPY
Net increase (decrease) in cash and cash equivalents
1,149,238,000 JPY
-657,493,000 JPY
Cash and cash equivalents
3,161,471,000 JPY
2,012,233,000 JPY
2,669,727,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.